KOL KnockoutTM: Glaucoma Edition - Personalized Treatment Pl

Name: KOL Knockout™: Glaucoma Edition - Personalized Treatment Plans in Medical Glaucoma Management - Round 3
Uploaded: 2022-04-22T04:00:00+00:00
Duration: 1 h 14 min 31 s
Description: Hosted by Douglas J. Rhee, MD, this championship round of KOL KnockoutTM: Glaucoma Edition features Round #2 Winner Thomas D. Patrianakos, DO, along with c

Overview
Hosted by Douglas J. Rhee, MD, this championship round of KOL Knockout^TM: Glaucoma Edition features Round #2 Winner Thomas D. Patrianakos, DO, along with contestants Leon W. Herndon Jr., MD, and Sameh Mosaed, MD.
The program includes a brief presentation followed by patient case studies. The panel members weighed in on treatment options. This content was captured during a live virtual symposium. Voting took place during the symposium.
This activity is supported by an unrestricted educational grant from Aerie Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe the MOA of novel therapeutics and classes of drugs.
- Restate the most common side effects of novel therapeutics and explain the likelihood of achieving target intraocular pressure with monotherapy compared with combination regimens.
- Discuss the differences of branded versus generic glaucoma agents and identify patients at heightened risk for loss to follow-up.
- Evaluate and explain to patients the latest available treatments and determine which option is best for each patient.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Douglas J. Rhee, MD
Chair, Department of Ophthalmology and Visual Sciences
Director, University Hospitals Eye Institute
Case Western Reserve University School of Medicine
Cleveland, OH

Leon W. Herndon Jr, MD
Professor of Ophthalmology
Chief of Glaucoma Division
Duke Eye Center
Durham, NC

Sameh Mosaed, MD
Professor of Ophthalmology
Director of Glaucoma
The Gavin Herbert Eye Institute
University of California, Irvine
Irvine, CA

Thomas D. Patrianakos, DO
Chair of Ophthalmology
Cook County Health
Chicago, IL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Douglas J. Rhee, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Advisory Board: Ocular Therapeutix. Consultant: Aerie Pharmaceuticals, Allergan, and Ivantis. Grant/Research Support: Allergan, Glaukos, and Ivantis. Speaker’s Bureau: Aerie and Ivantis.
Leon W. Herndon Jr, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie, Alcon, Allergan, Genentech, Glaukos, New World Medical, Ocular Therapeutix, and Sight Sciences. Speaker's Bureau: Allergan and Genentech.
Sameh Mosaed, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Grant/Research Support: Sight Sciences. Speaker's Bureau: Aerie Pharmaceuticals and Bausch + Lomb.
Thomas D. Patrianakos, DO, has had no financial agreements or affiliations with ineligible companies.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Aerie Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/22/2022